PRIMARY MEMBRANOUS NEPHROPATHY
Clinical trials for PRIMARY MEMBRANOUS NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEMBRANOUS NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY MEMBRANOUS NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial aims to halt damaging kidney leak
Disease control OngoingThis study is testing whether the drug zanubrutinib can help control primary membranous nephropathy, a serious autoimmune kidney disease. It will compare zanubrutinib against an existing drug, tacrolimus, in about 178 adults who are already on standard supportive care. The main g…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE2, PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug trial aims to control serious kidney disease
Disease control OngoingThis study is comparing two treatments for primary membranous nephropathy, a kidney disease where the body's immune system attacks the kidneys, causing protein loss. About 142 adults with this condition will receive either the study drug obinutuzumab or the standard drug tacrolim…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug trial offers hope for patients with rare kidney disease
Disease control OngoingThis study is testing a new drug called Zuberitamab (HS006) for people with primary membranous nephropathy, a serious autoimmune kidney disease that causes protein loss. It will compare Zuberitamab to an existing drug, cyclosporine, to see which is better at reducing protein in t…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Global kidney disease treatment trial withdrawn before starting
Disease control TerminatedThis international study aimed to compare two different treatment approaches for adults with primary membranous nephropathy, a serious kidney condition that causes protein loss in urine. The trial planned to test whether a newer medication called obinutuzumab works better than th…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC